9 Meters Biopharma Inc.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is de… Read more
9 Meters Biopharma Inc. (NMTRQ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2023: 1.548x
Based on the latest financial reports, 9 Meters Biopharma Inc. (NMTRQ) has a cash flow conversion efficiency ratio of 1.548x as of March 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.75 Million) by net assets ($-6.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
9 Meters Biopharma Inc. - Cash Flow Conversion Efficiency Trend (2019–2022)
This chart illustrates how 9 Meters Biopharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
9 Meters Biopharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 9 Meters Biopharma Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Critical Metals Plc
LSE:CRTM
|
-0.534x |
|
Videndum Plc
LSE:VID
|
-0.201x |
|
A Capital Holding
EGX:ACAP
|
N/A |
|
ESPRIT HLDGS - Dusseldorf Stock Exchang
DU:ESHB
|
N/A |
|
Alliance Witan Ord
LSE:ALW
|
0.006x |
|
IMC Exploration Group Public Limited Company
LSE:IMC
|
-0.044x |
|
Unity Metals Limited
AU:UM1
|
-1.287x |
|
OUT
WAR:OUT
|
N/A |
Annual Cash Flow Conversion Efficiency for 9 Meters Biopharma Inc. (2019–2022)
The table below shows the annual cash flow conversion efficiency of 9 Meters Biopharma Inc. from 2019 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $2.40 Million | $-37.24 Million | -15.514x | -2089.59% |
| 2021-12-31 | $41.60 Million | $-29.48 Million | -0.709x | -17.34% |
| 2020-12-31 | $32.14 Million | $-19.41 Million | -0.604x | -132.31% |
| 2019-12-31 | $-9.61 Million | $-17.97 Million | 1.869x | -- |